The Medical Letter on Drugs and Therapeutics
- Auvi-Q Epinephrine Auto-Injector Returns
- Crisaborole (Eucrisa) for Atopic Dermatitis
- Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
- Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
- Kyleena - Another Hormonal IUD
- Drug Interaction: Clopidogrel and PPIs
- Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
Auvi-Q Epinephrine Auto-Injector Returns
February 27, 2017 (Issue: 1515)Auvi-Q (Kaléo; previously manufactured and marketed by Sanofi), the epinephrine auto-injector approved by the FDA in 2012 for emergency treatment of anaphylaxis and voluntarily withdrawn in 2015 due to potential inaccurate dosage delivery,...more
- FDA. Updated: Sanofi US issues voluntary nationwide recall of all Auvi-Q due to potential inaccurate dosage delivery. Available at www.fda.gov. Accessed February 6, 2017.
- ES Edwards et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol 2013; 111:132.
- CA Camargo Jr. et al. Auvi-Q versus EpiPen: preferences of adults, caregivers, and children. J Allergy Clin Immunol Pract 2013; 1:266.
- T Umasunthar et al. Patients' ability to treat anaphylaxis using adrenaline autoinjectors: a randomized controlled trial. Allergy 2015; 70:855.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.